UK NICE guide on NHS use of S-P's Temodal

30 April 2001

The National Institute for Clinical Excellence has advised the NationalHealth Service in England and Wales that Schering-Plough's Temodal (temozolomide) may be offered as second-line chemotherapy treatment for patients suffering from recurrent malignant glioma (brain cancer) in the following circumstances:

- the patients have a tumor that has been shown to be malignant through microscopic examination of the tumor cell; - imaging tests have shown that the tumor has recurred or is progressing; - they have a Karnofsky performance status greater than or equal to 70; and - it is expected that they will live for 12 weeks or more at the start of treatment with the drug.

Temodal is only recommended as initial chemotherapy treatment for patients with brain cancer when they are taking part in a clinical trial.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.